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Introduction: Patients with stage III non–small-cell lung cancer 
and poor performance status and/or weight loss do not seem to 
benefit from standard therapy. Based on the preclinical interaction 
between epidermal growth factor receptor inhibitors and radiation, 
we designed a trial of induction chemotherapy followed by thoracic 
radiotherapy and concurrent erlotinib.
Methods: Patients with poor-risk unresectable stage III non–small-
cell lung cancer received two cycles of carboplatin at an AUC of 
5 and nab-paclitaxel at 100 mg/m2 on days 1 and 8 every 21 days, 
followed by erlotinib administered concurrently with thoracic radio-
therapy. Maintenance was not permitted. Molecular analysis was 
performed in available specimens. Seventy-two eligible patients were 
required to test whether the 1-year survival rate was less than 50% 
or greater than or equal to 65% with approximately 90% power at a 
significance level of 0.10.
Results: From March 2008 to October 2011, 78 patients were 
enrolled, three of whom were ineligible. The median age was 68 
(range, 39–88) and 32% were aged greater than or equal to 75 years. 
Patients were evenly distributed between stages IIIA and IIIB and 
the majority had performance status 2. The overall response rate was 
67% and the disease control rate was 93%. Treatment was well toler-
ated. The median PFS and OS were 11 and 17 months, respectively. 
The overall 12-month OS was 57%, which narrowly missed the pre-
specified target for significance.
Conclusions: Patients with poor-risk stage III non–small-cell lung 
cancer had better than expected outcomes with a regimen of induc-
tion carboplatin/nab-paclitaxel followed by thoracic radiotherapy and 
erlotinib. However, as per the statistical design, the 12-month OS was 
not sufficiently high to warrant further studies.
Key Words: Poor risk, Stage III, NSCLC.
(J Thorac Oncol. 2015;10: 143–147)
Patients with locally advanced non–small-cell lung can-cer (NSCLC) treated with concurrent chemotherapy and 
thoracic radiotherapy (TRT) have a 20% to 25% probability 
of long-term disease-free survival.1 However, patients with 
adverse prognostic features, such as poor performance status 
(PS) and/or significant weight loss, which represent a siz-
able percentage of patients, have a worse prognosis and do 
not seem to benefit from the standard approach.2 No specific 
treatment guidelines exist for this subset and management 
options in clinical practice range from palliative radiotherapy 
to sequential treatment or an attenuated concurrent approach.
Building on the preclinical rationale that inhibitors of 
the epidermal growth factor receptor (EGFR) are strong radia-
tion sensitizers,3 the Cancer and Leukemia Group B (CALGB 
30106) published a trial in which a subset of 21 patients with 
locally advanced disease and poor PS were treated with induc-
tion chemotherapy followed by gefitinib, an EGFR tyrosine 
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kinase inhibitor, administered concomitantly with TRT.4 The 
median survival was an unprecedented 19 months, which 
could not be accounted for by the few patients with EGFR-
mutated tumors.
Based on this experience, we designed a phase II trial 
of two cycles of induction chemotherapy with carboplatin and 
nab-paclitaxel followed by TRT and concurrent erlotinib for 
patients with stage IIIA/B NSCLC and poor-risk features. 
Molecular evaluation for EGFR mutations was performed in 
available tumor specimens. The trial was conducted by the 
former CALGB, now Alliance for Clinical Trials in Oncology, 
and the former Radiation Therapy Oncology Group, now 
NRG Oncology.
PATIENTS AND METHODS
Patients with histologically or cytologically documented 
NSCLC, with unresectable stage IIIA or IIIB by the AJCC 
version 6 staging system (T1-3 N2; T4 N0-2; and N3 patients 
except for contralateral hilar or supraclavicular involvement), 
were eligible if they had either PS 2 or PS 0-1 and greater than 
or equal to 10% weight loss within 3 months before enroll-
ment. A formal distinction between a PS 2 on the basis of can-
cer-related impairment versus preexisting co-morbidities was 
not made but the ECOG scale, which was used for eligibil-
ity purposes, implies the latter. Before chemotherapy, radio-
therapy, or targeted therapy was not permitted. Measurable 
disease was required, as was normal renal, liver, and bone 
marrow function. A positron emission tomography scan was 
encouraged but not mandated. Evaluation by a medical and 
a radiation oncologist before study enrollment was required. 
Participation in the correlative molecular component had to be 
offered but patients could opt out.
Patients received two cycles of induction chemotherapy 
with carboplatin and nab-paclitaxel. The first 17 patients were 
treated, respectively, with an AUC of 6 and 100 mg/m2 on days 
1, 8, and 15 every 28 days. A preliminary toxicity analysis 
showed high rates of grade 3 (29%) and grade 4 (18%) neu-
tropenia, which led to several day 15 omissions, and prompted 
a protocol modification to carboplatin to an AUC of 5 and the 
nab-paclitaxel to be administered on days 1 and 8 every 21 
days (same doses). Erlotinib at a dose of 150 mg daily was 
administered from day 1 of TRT until its completion.
Radiation started on week 7, assuming no evidence of 
progressive disease (PD) and recovery from chemotherapy-
induced toxicities. Radiation was delivered at 2 Gy/d 5 days/
wk for 33 fractions and a total dose of 66 Gy. Radiation 
planning was based on postinduction scans but originally 
involved lymph node regions were included in the treat-
ment volume. There was no elective nodal irradiation. All 
patients were treated with three-dimensional conformal 
radiotherapy; IMRT was not allowed. The use of systems to 
control or compensate for respiratory motion was permitted. 
Quality assurance was performed by the Quality Assurance 
Review Center, and the Chair of the Alliance RT committee. 
Response was evaluated after induction therapy (8 weeks), 
after concurrent therapy (16 weeks), and then every 3 
months for 1 year and every 6 months until relapse. Patients 
with PD outside the chest after induction chemotherapy were 
removed from protocol therapy. Patients with progression of 
intrathoracic disease within the potential radiation field were 
considered for protocol therapy after consultation with the 
study chairs.
The primary objective of this phase II trial was overall 
survival (OS) at 12 months. Secondary objectives included 
response rate, progression-free survival, and correlation of 
tumor biomarkers with clinical outcomes. Overall survival 
was defined as the time from registration to death of any 
cause. Progression-free survival was defined as the time from 
registration to disease progression or death of any cause, 
whichever came first. Treatment was deemed a “success” 
if the patient remained alive for at least 12 months. With 
72 eligible patients, the trial was designed to test the null 
hypothesis that the treatment success rate was less than 50% 
against the alternative hypothesis that the treatment success 
rate was greater than 65% at a one-sided Type I error of 0.10 
and 90% power. A two-stage phase II design was used to 
allow early stopping for futility: if less than 19 of the first 
40 eligible patients were alive at 12 months, the trial would 
be stopped. Otherwise, it would proceed to full accrual. If 
42 or more “successes” were observed, corresponding to a 
12-month survival of 58.3%, further investigation of this 
regimen would be warranted. For secondary analyses, OS 
and PFS were estimated with the Kaplan–Meier method. 
Subgroup analyzes based on PS (0.1 versus 2) and stages 
(IIIA versus IIIB) were displayed by Kaplan–Meier curves 
and tested by log rank tests.
Data collection and statistical analyses were conducted 
by the Alliance Statistics and Data Center. Data quality was 
ensured by review of data by the Alliance Statistics and Data 
Center and by the study chairperson following Alliance poli-
cies. Each participant signed an Institutional Review Board–
approved, protocol-specific informed consent in accordance 
with federal and institutional guidelines.
RESULTS
The study was activated in March 2008 and closed in 
October 2011. A total of 78 patients were registered, of which 
three patients did not receive protocol treatment and were 
therefore excluded from the analysis. Median age was 68 
years (range, 39–88); 32% of the patients were aged 75 years 
or older and another 41% were aged between 65 and 74 years. 
Patients were evenly distributed between stages IIIA (51%) 
and IIIB (49%). The majority of patients had PS 2 (64%), and 
55% of patients had a baseline positron emission tomography 
scan. The demographic data are shown in Table 1.
Protocol therapy was completed by 80% of patients. PD 
(5%) and adverse events (5%) were the two most common 
reasons for lack of completion. Response data included 8% 
complete response, 59% partial response, 27% stable disease, 
and 7% PD. The disease control rate (complete response + 
partial response + stable disease) was 93%. Of the 39 patients 
who relapsed, 16 had local relapse only, 12 had distant relapse 
only, and 11 had both local and distant relapse.
Overall, the toxicity results demonstrate the feasi-
bility of this approach (Table 2). After the amendment, the 
frequency of grades 3 to 4 neutropenia decreased to 7% and 
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3%, respectively. There was only one episode of documented 
febrile neutropenia. Grade 3 anemia was seen in 10% of 
patients. Grade 3 esophagitis was observed in 5% of patients 
and pneumonitis in 1% of the patients.
The median follow-up time was 40 months (Table 3). 
All 75 patients were followed for more than 12 months. The 
median PFS was 11 months (9, 16 months), and the median 
survival was 17 months (11, 22 months) for the entire pop-
ulation. Respective 12-month PFS and OS were 47% (95% 
confidence interval: 37%–59%) and 57% (95% confidence 
interval: 47%–70%). Outcomes by treatment strata by stage 
( Figure 1A) showed that patients with IIIA disease had a sig-
nificantly better PFS than stage IIIB patients: 16 versus 9 
months (p = 0.038); the respective median survival times were 
19 versus 12 months (p = 0.302).
Molecular data were available for 31 patients (42% of 
the eligible patients). Eleven of the samples contained between 
1% and 25% of tumor cells, which may have compromised the 
results. No patients with EGFR mutation were identified; two 
patients had tumors with KRAS mutations.
DISCUSSION
Our study is the largest cooperative group experience 
in poor-risk patients with stage III NSCLC. Furthermore, our 
study is the first to incorporate an EGFR tyrosine kinase inhib-
itor in the combined modality therapy of locally advanced 
NSCLC, along with a molecular evaluation of available tumor 
specimens.
Treatment was well tolerated despite the poor-risk fea-
tures and the advanced age of the population. After the initial 
dose and schedule adjustment, the combination of carboplatin 
and nab-paclitaxel proved to be quite tolerable, with no sig-
nificant hematologic complications. The same applies to the 
addition of erlotinib to TRT, which did not lead to an increase 
in esophagitis and/or pneumonitis. Erlotinib was not con-
tinued after definitive therapy based on the unfavorable out-
comes with gefitinib maintenance after combined modality 
therapy observed in the SWOG 0203 study.5
While the study results exceed the expected survival for 
this patient subset, the prespecified target for significance was 
narrowly missed. It can be argued that our target was unre-
alistic based on the available literature. In other words, the 
survival observed in the 21 poor risk patients in the CALGB 
30106 trial,4 which guided our statistical design, may not 
be reproducible in a larger sample size. Therefore, despite 
achieving remarkable outcomes for poor-risk patients with 
locally advanced NSCLC, we cannot conclusively reject the 
null hypothesis, i.e., that the addition of erlotinib to TRT pro-
vides no significant benefit over TRT alone after induction 
chemotherapy in patients not selected by molecular criteria.
Our finding of no EGFR-mutated tumor in the study 
population is unusual, as the presence of this molecular altera-
tion is expected in approximately 10% to 15% of patients in 
the United States. This underscores the fact that our results 
reflect a truly unselected study population. Furthermore, the 
TABLE 1.  Patient Characteristics (n = 75)
Characteristics
Age (median, range) 68 (39–88)
n (%)
Age (yr)
  <65 20 (27)
  65–74 31 (41)
  ≥75 24 (32)
Sex
  Male 44 (59)
  Female 31 (41)
Stage
  IIIA 38 (51)
  IIIB 37 (49)
Poor risk
  PS = 0.1 and WL ≥ 10% 27 (36)
  PS = 2 48 (64)
PS, performance status; WL, weight loss.
TABLE 2.  Treatment-Related Grades 3 to 4 Adverse Events
Grade 3 Grade 4
n (%) n (%)
Anemia 6 (8) 1 (1)
Neutropenia 9 (12) 5 (7)
Thrombocytopenia 3 (4) 0
Fatigue 12 (1) 1 (1)
Skin rash 3 (4) 0
Nausea/vomiting 3 (4) 0
Diarrhea 7 (9) 0
Esophagitis 4 (5) 0
Pulmonary 1 (1) 0
Infection 1 (1) 0
TABLE 3.  Efficacy Results (n = 75)
Response
  Complete response 6 (8%)
  Partial response 44 (59%)
  Stable disease 20 (27%)
  Progressive disease 5 (7%)
  Overall response rate 67%
PFS
  Median 11 mo
  12-month 47%
OS
  Median 17 mo
  12-month 57%
Stage IIIA vs. IIIB
  Median PFS 16 vs. 9 mo
  Median OS 19 vs. 12 mo
PS 0–1 + WL vs. PS 2
  Median PFS 16 vs. 10 mo
  Median OS 19 vs. 13 mo
OS, overall survival; PFS, progression-free survival; PS, performance status; WL, 
weight loss.
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lack of a subset of patients with EGFR-mutated tumors in 
our study prevents any hypothesis about the validity of this 
approach in selected patients.
Investigators at M.D. Anderson completed a phase II 
trial of chemotherapy intercalated with erlotinib and concur-
rent TRT in stage III NSCLC patients with PS 0 to 1.6 Forty-
six evaluable patients received carboplatin AUC = 2 and 
paclitaxel 45 mg/m2 administered every Monday and erlotinib 
150 mg orally on Tuesday–Sunday for 7 weeks throughout 
TRT, followed by two cycles of consolidation carboplatin–
paclitaxel. Median time to progression, the primary endpoint, 
was 13.6 months. Toxicity was acceptable and outcomes did 
not differ according to EGFR status (4 of the 41 patients tested 
had EGFR-mutated tumors). The investigators concluded that 
this approach, while effective, did not lead to survival out-
comes that justified pursuing it further.
Other trials of EGFR inhibitors given concurrent with 
TRT in locally advanced disease have been recently reported. 
Radiation Therapy Oncology Group 0617 was a large phase 
III trial with a 2 × 2 factorial design, which included an evalu-
ation of cetuximab, an EGFR-directed monoclonal antibody, 
in combination with chemotherapy. The results showed no 
advantage for the addition of cetuximab.7
The National Cancer Institute has recently approved a 
large phase III cooperative group trial of a molecular-based 
approach in stage III NSCLC, in which erlotinib or crizotinib 
is given as a single agent for 3 months in patients with EGFR 
mutations or ALK rearrangements, respectively, followed by 
concurrent chemotherapy and TRT.8 This study will determine 
the value of targeted agents in stage III patients with action-
able mutations. In our trial, the results of the molecular com-
ponent showed no EGFR mutations, which impeded clinical 
correlation.
Efforts to investigate poor-risk patients with locally 
advanced NSCLC remain meager despite the unmet need. 
These patients are treated with a variety of approaches in 
clinical practice and may at times receive substandard therapy, 
which leads to worse outcomes and, in a circular argument, 
reinforces the bias that treatment is ineffective. However, at 
this time, it is not obvious which research venue to pursue to 
test more appropriate treatments in this patient subset.
In conclusion, a strategy of induction chemotherapy with 
a well-tolerated combination regimen, followed by definitive 
TRT and concomitant erlotinib, yielded favorable results but 
failed to reach a prespecified level of statistical significance. 
New strategies are required to improve the outcome of poor 
prognosis patient with locally advanced NSCLC.
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FIGURE 1. A, Progression-free 
survival (PFS) by stage. B, Overall 
survival (OS) by stage.
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